M

Madrigal Pharmaceuticals
D

MDGL

298.42
USD
-0.49
(-0.16%)
مغلق
حجم التداول
16,303
الربح لكل سهم
-17
العائد الربحي
-
P/E
-17
حجم السوق
6,625,903,414
أصول ذات صلة
E
EXEL
0.790
(1.76%)
45.600 USD
INSM
INSM
0.420
(0.41%)
103.950 USD
K
KPTI
-0.10000
(-2.24%)
4.36000 USD
المزيد
الأخبار المقالات

العنوان: Madrigal Pharmaceuticals

القطاع: Healthcare
الصناعة: Biotechnology
Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, and premature mortality. The company's medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor agonist designed to target key underlying causes of MASH.